NVIDIA launches Jetson Thor robotics computers for physical AI systems
LONG BEACH, Calif. - The Beauty Health Company (NASDAQ:SKIN) reported fourth-quarter 2024 results that exceeded analyst expectations for revenue, but the stock fell 2.9% as the company provided weak guidance for the upcoming year.
The maker of Hydrafacial skincare devices posted revenue of $83.5 million for the quarter, surpassing the consensus estimate of $77.39 million. This represents a 13.8% decrease compared to the same quarter last year. The company reported an adjusted loss per share of $0.08, which was better than the analyst estimate of a $0.11 loss.
Beauty Health’s consumables net sales increased to $56.7 million from $52.2 million YoY, while delivery systems net sales declined to $26.8 million from $44.6 million. The company ended the year with an estimated active install base of 34,735 units, up from 31,446 in the prior year.
CEO Marla Beck commented, "In Q4 2024, we continued to strengthen our financial position, exceeding the high end of our guidance for both net sales and adjusted EBITDA."
Despite the revenue beat, Beauty Health’s stock declined following the earnings release, likely due to its weak guidance for 2025. The company expects full-year 2025 revenue between $270 million and $300 million, which is below the current year’s $334.3 million and analyst expectations of $332.5 million. Adjusted EBITDA for 2025 is projected to be between $10 million and $25 million.
The company cited near-term global macroeconomic uncertainty and industry headwinds as factors affecting its outlook. Beauty Health is focusing on deepening partnerships, accelerating innovations, and enhancing commercial execution to drive long-term shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.